Smith & Nephew plc (SNN) Q1 2026 Sales/Trading Call Transcript

Smith & Nephew said Q1 2026 underlying growth was 3.1%, or 4.7% on an adjusted daily basis, in line with expectations. Growth was broad-based across business units and regions, with strong Sports Medicine and resilient Advanced Wound Management offsetting softer U.S. knees and CMS reimbursement headwinds. Management characterized the quarter as a good start to the year, signaling steady underlying fundamentals rather than a major surprise.

Analysis

The read-through is less about a clean top-line beat and more about mix management: the company is effectively admitting it is sacrificing some near-term knee volume to protect longer-cycle economics in better-growth categories. That usually helps margins and reduces inventory risk, but it also makes the quarter look artificially steadier than underlying orthopedic demand, which matters because consensus will likely extrapolate too much from a single “in-line” print.

The second-order winner is any supplier or competitor tied to higher-acuity sports medicine and wound care workflows, while pure-play knee exposure should see relative pressure if this discipline persists into the next quarter. The CMS reimbursement headwind in wound care is important beyond the segment itself: if managed-care sensitivity or reimbursement resets spread, hospital purchasing behavior can become more conservative across adjacent products, compressing conversion cycles for several months.

The key catalyst window is 1-2 quarters, not 1-2 days. If U.S. knees remain soft while the rest of orthopedics only grows modestly, investors will start treating the portfolio as a “good categories, bad category offset” story rather than a broad cyclical recovery, which caps multiple expansion. Conversely, if the company can show that the knee trade-off is intentional and temporary while sports medicine continues to outgrow, the market may pay up for better quality and lower volatility into the second half.

Contrarian angle: the market may be underestimating how defensible this is if management is truly reallocating resources away from lower-return volume. That can look like slower growth today but better incremental ROIC, which is exactly the kind of setup that rerates over 6-12 months if investors stop focusing on headline growth and start focusing on earnings durability.

Key Decisions for Investors

• Long SNN on pullbacks for a 3-6 month horizon: the setup favors improving mix and margin quality more than explosive revenue acceleration; risk/reward is attractive if the market misreads deliberate knee softness as demand weakness.
• Pair trade: long SNN / short a more knee-dependent ortho peer for 1-2 quarters; thesis is that portfolio diversification and sports medicine strength should outperform single-segment orthopedic exposure if procedure volumes stay uneven.
• Avoid chasing the move intraday; wait for confirmation in the next trading update that U.S. knee softness is contained. If knees do not stabilize by the next print, de-rate the thesis and reduce exposure.
• Consider a limited-risk call spread in SNN over the next 3-6 months if implied vol remains subdued; the upside is a rerating on quality/mix, while downside is capped if orthopedic growth stays mixed.
• Watch CMS-sensitive wound care names for 1-2 quarter earnings revisions; if reimbursement pressure broadens, use any strength in those names to short into, as the market may be underpricing duration risk.